跳至主要内容
临床试验/JPRN-C000000051
JPRN-C000000051已完成1 期

A phase I/II study of hepatic arterial 5-flurouracil (5FU) combined with intravenous irinotecan hydrochloride (CPT-11) for metastatic colorectal cancer isolated in the liver. (JCOG 0208-DI) - A phase I/II study of hepatic arterial 5FU combined with intravenous CPT-11 for metastatic colorectal cancer isolated in the liver. (JCOG 0208-DI)

Japan Clinical Oncology Group(JCOG)0 个研究点目标入组 30 人开始时间: 2005年8月8日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 70years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Massive pleural effusion or massive ascites. 2) Active bleeding from digestive organ. 3) Active infection. 4) Watery diarrhea. 5) Other uncontrolled severe illness. 6) Active other malignancy. 7) Prior radiation therapy for abdomen. 8) Positive hepatitis-B antigen or anti-hepatitis-C antibody. 9) Allergy to iodine contrast medium resulting in preclusion of angiography. 10) Severe mental disorder. 11) Pregnant or nursing. 12) Prior placement of hepatic arterial catheter and port system.

研究者

发起方
Japan Clinical Oncology Group(JCOG)

相似试验